SKK
ALXN

Shepherd Kaplan Krochuk’s Alexion Pharmaceuticals ALXN Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,423
Closed -$236K – 572
2014
Q3 		$236K Sell
1,423
-164
-10% -$26.9K 0.03% 406
2014
Q2 		$248K Buy
1,587
+108
+7% +$17.1K 0.03% 403
2014
Q1 		$225K Buy
+1,479
New +$235K 0.03% 424

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Shepherd Kaplan Krochuk's ALXN Position: Q4 2014 in Review

Shepherd Kaplan Krochuk sold out of Alexion Pharmaceuticals (ALXN) in Q4 2014, closing a stake of 1,423 shares — an estimated $236K sold.

Shepherd Kaplan Krochuk first reported a position in ALXN in Q1 2014 and held it in 3 quarters. The position peaked at $248K in Q2 2014. 579 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

  • Shepherd Kaplan Krochuk reported no remaining Alexion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 1,423 Alexion Pharmaceuticals shares in Q4 2014, an estimated $236K.
  • Shepherd Kaplan Krochuk first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Shepherd Kaplan Krochuk's Alexion Pharmaceuticals position peaked at $248K in Q2 2014.
  • 579 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Shepherd Kaplan Krochuk's 13F filing for Q4 2014, filed 17 Feb 2015.